NYKD · NYKODE THERAPEUTICS ASA · Financials
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Browse captured authority reports and their original financial labels
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| $0 | $8.68M | $12.9M | |
| $2.04M | $2.25M | $2.12M | |
| -$28.59M | -$48.33M | -$58.08M | |
| — | -556.87% | -450.18% | |
| -$26.55M | -$46.08M | -$55.96M | |
| $2.4M | $6.18M | $4.68M | |
| -$17.7M | -$45.51M | -$44.09M | |
| -$5.46M | -$6.69M | -$8.93M | |
| -$12.24M | -$38.82M | -$35.15M | |
| — | -447.3% | -272.47% | |
| USD/shares | -$0.04 | -$0.12 | -$0.12 |
| USD/shares | -$0.04 | -$0.12 | -$0.12 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $32.28M in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.